"Histones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Small chromosomal proteins (approx 12-20 kD) possessing an open, unfolded structure and attached to the DNA in cell nuclei by ionic linkages. Classification into the various types (designated histone I, histone II, etc.) is based on the relative amounts of arginine and lysine in each.
| Descriptor ID |
D006657
|
| MeSH Number(s) |
D12.776.157.687.485 D12.776.660.720.485 D12.776.664.469
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Histones".
Below are MeSH descriptors whose meaning is more specific than "Histones".
This graph shows the total number of publications written about "Histones" by people in this website by year, and whether "Histones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 1 | 3 |
| 1996 | 7 | 2 | 9 |
| 1997 | 3 | 3 | 6 |
| 1998 | 4 | 1 | 5 |
| 1999 | 1 | 3 | 4 |
| 2000 | 3 | 3 | 6 |
| 2001 | 4 | 7 | 11 |
| 2002 | 7 | 5 | 12 |
| 2003 | 13 | 12 | 25 |
| 2004 | 8 | 7 | 15 |
| 2005 | 11 | 14 | 25 |
| 2006 | 22 | 25 | 47 |
| 2007 | 13 | 32 | 45 |
| 2008 | 13 | 21 | 34 |
| 2009 | 16 | 34 | 50 |
| 2010 | 19 | 28 | 47 |
| 2011 | 23 | 28 | 51 |
| 2012 | 22 | 29 | 51 |
| 2013 | 26 | 38 | 64 |
| 2014 | 14 | 34 | 48 |
| 2015 | 13 | 21 | 34 |
| 2016 | 24 | 30 | 54 |
| 2017 | 18 | 25 | 43 |
| 2018 | 20 | 16 | 36 |
| 2019 | 16 | 21 | 37 |
| 2020 | 12 | 27 | 39 |
| 2021 | 14 | 20 | 34 |
| 2022 | 9 | 8 | 17 |
| 2023 | 8 | 8 | 16 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Histones" by people in Profiles.
-
Neural tube defects and epigenetics: role of histone post-translational histone modifications. Epigenomics. 2024 Mar; 16(6):419-426.
-
CPSF3 inhibition blocks pancreatic cancer cell proliferation through disruption of core histone mRNA processing. RNA. 2024 Feb 16; 30(3):281-297.
-
An ERK5-PFKFB3 axis regulates glycolysis and represents a therapeutic vulnerability in pediatric diffuse midline glioma. Cell Rep. 2024 01 23; 43(1):113557.
-
EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes. Cancer Res. 2023 12 01; 83(23):3956-3973.
-
Molecular Basis for SPINDOC-Spindlin1 Engagement and Its Role in Transcriptional Attenuation. J Mol Biol. 2024 Apr 01; 436(7):168371.
-
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. Cancer Discov. 2023 11 01; 13(11):2370-2393.
-
Rare de novo gain-of-function missense variants in DOT1L are associated with developmental delay and congenital anomalies. Am J Hum Genet. 2023 11 02; 110(11):1919-1937.
-
Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer. Autophagy. 2024 01; 20(1):114-130.
-
Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation. Cell. 2023 08 31; 186(18):3945-3967.e26.
-
A de novo missense variant in EZH1 associated with developmental delay exhibits functional deficits in Drosophila melanogaster. Genetics. 2023 08 09; 224(4).